Martin Löwer
Impact in
- Immunology top 0.5%
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
- T-cell and B-cell Immunology
- Oncology top 1%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
Papers in
-
- vaccines and immunoinformatics approaches 13
- RNA Interference and Gene Delivery 5
- Immunology 21
- Immunotherapy and Immune Responses 15
- Co-authors
- Uğur Şahin (33 shared papers)Özlem Türeci (16 shared papers)Barbara Schrörs (16 shared papers)Sebastian Boegel (10 shared papers)Mustafa Diken (11 shared papers)John C. Castle (4 shared papers)Sebastian Kreiter (8 shared papers)Christoph Huber (2 shared papers)
- Journals
- PLoS ONE (6 papers)Annals of Oncology (3 papers)Nature Reviews Drug Discovery (2 papers)Bioinformatics (2 papers)Genome Medicine (2 papers)
- Partner nations
- GermanySwitzerlandUnited States
In The Last Decade
Martin Löwer
45 papers receiving 4.2k citations
Martin Löwer's Hit Papers
Peers
Comparison fields: 5 of 112
- Immunology 2.3k
- Oncology 1.7k
- Molecular Biology 1.8k
- Cancer Research 330
- Endocrinology 89
Countries citing papers authored by Martin Löwer
This map shows the geographic impact of Martin Löwer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Martin Löwer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Martin Löwer more than expected).
Fields of papers citing papers by Martin Löwer
This network shows the impact of papers produced by Martin Löwer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Martin Löwer. The network helps show where Martin Löwer may publish in the future.
Co-authors
The 25 scholars most cited alongside Martin Löwer, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 45 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Mutant MHC class II epitopes drive therapeutic immune responses to cancer Hit paper breakdown → | 2015 | 934 |
| 2 | Exploiting the Mutanome for Tumor Vaccination Hit paper breakdown → | 2012 | 625 |
| 3 | Identification of neoantigens for individualized therapeutic cancer vaccines Hit paper breakdown → | 2022 | 349 |
| 4 | 2017 | 281 | |
| 5 | 2018 | 249 | |
| 6 | 2010 | 248 | |
| 7 | 2017 | 197 | |
| 8 | 2012 | 172 | |
| 9 | 2010 | 152 | |
| 10 | 2020 | 148 | |
| 11 | 2009 | 96 | |
| 12 | 2010 | 94 | |
| 13 | 2014 | 80 | |
| 14 | 2018 | 76 | |
| 15 | 2008 | 69 | |
| 16 | 2011 | 49 | |
| 17 | 2020 | 44 | |
| 18 | 2010 | 43 | |
| 19 | 2022 | 40 | |
| 20 | 2018 | 38 |
About Martin Löwer
Martin Löwer is a scholar working on Molecular Biology, Immunology, Cancer Research, Oncology and Genetics, having authored 45 papers that have together received 4.2k indexed citations. Recurring topics across this work include Immunotherapy and Immune Responses (15 papers), vaccines and immunoinformatics approaches (13 papers), Cancer Immunotherapy and Biomarkers (7 papers), Cancer Genomics and Diagnostics (6 papers), RNA Interference and Gene Delivery (5 papers), Monoclonal and Polyclonal Antibodies Research (5 papers), SARS-CoV-2 and COVID-19 Research (3 papers) and CAR-T cell therapy research (3 papers). The work is most often cited by research in Immunology (2.3k citations), Oncology (1.7k citations), Molecular Biology (1.8k citations), Cancer Research (330 citations) and Endocrinology (89 citations). Martin Löwer has collaborated with scholars based in Germany, Switzerland and United States. Frequent co-authors include Uğur Şahin, Özlem Türeci, Barbara Schrörs, Sebastian Boegel, Mustafa Diken, John C. Castle, Sebastian Kreiter, Christoph Huber, Jan Diekmann and Niels van de Roemer. Their work appears in journals such as PLoS ONE, Annals of Oncology, Nature Reviews Drug Discovery, Bioinformatics and Genome Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.